SEC Form 4 · accession 0000891293-15-000014
CTI BIOPHARMA CORP · CTIC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew Plunkett
Officer — EVP, Corporate Development
Period of report
Mar 21, 2015
Accepted (ET)
Mar 24, 2015 · 6:56 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000891293
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 21, 2015 | F | 59,784 | $1.935 | D | 787,439 | D | |
| Common Stock | Mar 23, 2015 | S | 1,600 | $1.95 | D | 785,839 | D | |
| Common Stock | Mar 23, 2015 | S | 7,903 | $1.955 | D | 777,936 | D | |
| Common Stock | Mar 23, 2015 | S | 28,197 | $1.96 | D | 749,739 | D | |
| Common Stock | Mar 23, 2015 | S | 11,700 | $1.965 | D | 738,039 | D | |
| Common Stock | Mar 23, 2015 | S | 5,184 | $1.97 | D | 732,855 | D | |
| Common Stock | Mar 23, 2015 | S | 2,216 | $1.975 | D | 730,639 | D | |
| Common Stock | Mar 23, 2015 | S | 2,330 | $1.98 | D | 728,309 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares withheld by CTIC to satisfy tax withholding obligations on the vesting of restricted stock.
- F2The sale was effected pursuant to a rule 10b5-1 trading plan.